Neuronal fractalkine acts via its receptor, CX3CR1, on microglia to regulate neuroinflammation. Conflicting results have been reported in studies employing CX3CR1 deficient (Cx3cr1 −/− ) mice. Here, compared to wild-type, endotoxin-treated neuron-glial Cx3cr1
Introduction
Microglia, when activated, can produce trophic and antiinflammatory factors, all of which serve to protect against potential insults in the central nervous system (CNS). Overactivated microglia, however, release pro-inflammatory, neurotoxic factors such as superoxide, nitric oxide (NO) and cytokines that contribute to the pathology of neurodegenerative conditions such as Parkinson's disease (PD). The conditions governing whether microglial activation is neuroprotective or neurotoxic are largely unknown.
Fractalkine (FKN, CX3CL1) is a unique chemokine that can exist either as a static membrane-bound glycoprotein mediating cell adhesion or, after proteolytic cleavage, a soluble chemoattractant. Fractalkine, primarily expressed by neurons, is the sole ligand for its specific receptor, CX3CR1, which is present only on microglia (Harrison et al., 1998; Nishiyori et al., 1998; Ransohoff and Cardona, 2010) . Fractalkine has been proposed to be an inhibitory signal, tonically regulating the activation of microglia to maintain them in a quiescent state (Ransohoff and Perry, 2009 ).
Several studies have demonstrated that fractalkine acts to protect neurons in vitro in lipopolysaccharide (LPS)-activated microglia by limiting their release of inflammatory factors (Mizuno et al., 2003) . Most notably, treatment of cultured microglia with fractalkine has been demonstrated to dose-dependently suppress LPS-induced activation by reducing their production of NO, IL-6, TNF-α (Mizuno et al., 2003; Lyons et al., 2009) . While there is a consensus among studies for a neuroprotective role of fractalkine signaling in vitro, in vivo studies of CX3CR1-deficient mice have proven controversial. Although a neuroprotective role for CX3CL1-CX3CR1 signaling has been supported in studies of CX3CR1-deficient mouse models of amyotrophic lateral sclerosis (ALS), PD (Cardona et al., 2006) , and multiple sclerosis (MS) (Huang et al., 2006) , a neurotoxic role for fractalkine signaling has been demonstrated in studies using transgenic mice lacking CX3CR1 as animal models for Alzheimer's Disease (AD) (Liu et al., 2010) , stroke (Dénes et al., 2008) , and spinal cord injury (Donnelly et al., 2010) . The reasons for these contradictory reports are unclear.
To control for differences in preparation and treatment that limit cross-study comparisons, we compared microglial responsiveness to LPS in mixed neuron-glia cultures from Cx3cr1 −/− mice, wild-type mice, and BV-2 (immortalized microglia) cells. Our study confirmed a neuroprotective role for CX3CL1-CX3CR1 signaling in primary neuron-glia cultures from wild-type mice and BV-2 cells expressing siRNA against CX3CR1, but not in mixed cultures from Cx3cr1 −/− mice, which exhibited a reduced production of TNF-α, NO and superoxide. These in vitro results are in agreement with in vivo studies demonstrating a neurotoxic role for CX3CL1-CX3CR1 signaling. Because the application of exogenous fractalkine to both wild-type neuron-glia cultures and BV-2 cells led to a reduction in the LPS-induced production of E-mail address: zhangj@uw.edu (J. Zhang). 1 Authors who contributed to the work equally.
